SHANGHAI, June 16, 2025 /PRNewswire/ --?Abbisko Therapeutics (HKEX Code: 02256) today announced tha...
SHANGHAI, June 10, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced t...
SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its s...
SHANGHAI, May 13, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced th...
SHANGHAI, April 27, 2025 /PRNewswire/ --?Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics?02256...
SHANGHAI, March 31, 2025 /PRNewswire/ -- On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., ...
SHANGHAI, Dec. 8, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announc...
SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce ...
SHANGHAI, June 27, 2024 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) annou...
SHANGHAI, April 8, 2024 /PRNewswire/ -- 9 April 2024 (Beijing Time),?Abbisko Therapeutics Co., Ltd....
SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKE...
SHANGHAI, Dec. 13, 2023 /PRNewswire/ --?Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") tod...
SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has e...
SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" herea...
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" here...
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko" hereafter)?announ...
SHANGHAI, May 28, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" herea...
SHANGHAI, April 17, 2023 /PRNewswire/ -- Abbisko (Stock Code: 2256.HK) announced the results of fiv...
This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib(ABSK02...
SHANG HAI, March 2, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" her...